Dr. Gary M. Hochheiser is the Director of Thoracic Surgery and Thoracic Oncology at Maine Medical Center and the Medical Director for the facility’s Lung Screening Program. He specializes in the use of minimally invasive procedures for the treatment of malignant pleural mesothelioma, lung cancer, and esophageal cancer, as well as benign thoracic diseases. He
Dr. Anthony R. Lanfranco is an interventional pulmonologist and critical care specialist at Penn Medicine in Philadelphia. He specializes in numerous procedures integral to the care of patients with malignant pleural mesothelioma, lung cancer, and other pleural and lung diseases, including airway stenting, bronchial stenosis, bronchoscopy, cryotherapy, endoscopic lung volume reduction, and laser bronchoscopy. Education
Dr. Pettiford is a surgical oncologist with a focus on thoracic surgery at Ochsner M.D. Anderson Cancer Center in New Orleans, Louisiana. He has extensive experience in the treatment of malignant pleural mesothelioma and the use of robotic surgery for the treatment of lung cancer, benign lung disease, and esophageal cancer as well as benign
For decades, the world has understood asbestos’ role in the development of malignant mesothelioma, lung cancer, and other diseases. Despite this universal knowledge and countless people facing the realities of these painful asbestos-related illnesses, profit-focused companies continue defying protective regulations for asbestos management. In response to one such case, the attorney general of Massachusetts has
Dr. Borghaei is a medical oncologist and specialist in the treatment of lung cancer and malignant pleural mesothelioma at Fox Chase Cancer Center in Philadelphia, Pennsylvania. He holds the positions of Chief of Thoracic Medical Oncology, Professor in The Department of Hematology/Oncology at Fox Chase Cancer Center, and the Gloria and Edmund M. Dunn Chair
Dr. Christian Rolfo is a noted medical oncologist and specialist in the treatment of malignant pleural mesothelioma and lung cancer with the Mount Sinai Health System in New York City. He holds the positions of Professor of Medicine and Associate Director of Clinical Research in the Center of Thoracic Oncology at The Tisch Cancer Institute.
A combination of two immunotherapy drugs delivered an “encouraging” response rate in patients with advanced solid tumors, offering new hope for improvement in mesothelioma treatments. The clinical trial revealed a 37.7% objective response to treatment with anti-CTLA-4 human immunoglobulin (Ig) G1 monoclonal antibody CS1002 and the anti-PD-1 humanized recombinant IgG4 monoclonal antibody CS1003, also known
Dr. Corey J. Langer is a medical oncologist and Director of Thoracic Oncology at the Hospital of the University of Pennsylvania and Abramson Cancer Center in Philadelphia, Pennsylvania. He specializes in the treatment of patients diagnosed with lung cancers and malignant pleural mesothelioma and is particularly effective in the use of targeted treatment protocols that
Dr. David Harpole is a thoracic surgeon whose areas of expertise include mesothelioma surgery, thoracic oncologic surgery, lung cancer surgery, surgery for congenital and acquired chest wall abnormalities, and esophageal cancer surgery at the Duke Cancer Institute in Durham, North Carolina. He specializes in minimally invasive thoracic surgery. Dr. Harpole has been in practice for
Dr. Luis J. Herrera specializes in the surgical treatment of tumors of the chest, including malignant pleural mesothelioma, lung cancer, and cancers of the esophagus, mediastinum, and chest wall. He practices at Orlando Health Cancer Institute, where he is the medical director of the Rod Taylor Thoracic Care Center. Dr. Herrera has expertise in a